4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazine-1-carboxylic acid 1-acetoxy-ethyl ester | 1036708-93-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫氮卓类
• 英文名称: 4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazine-1-carboxylic acid 1-acetoxy-ethyl ester
• 英文别名: 1-Acetyloxyethyl 4-benzo[b][1,4]benzothiazepin-6-ylpiperazine-1-carboxylate
• CAS: 1036708-93-6
• 化学式: C₂₂H₂₃N₃O₄S
• 分子量: 425.508
• InChiKey: KYAPKJNXVFFXCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  96.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  11-(1-哌嗪基)二苯并[B,F][1,4]硫氮杂卓 、 1-{[(4-nitrophenoxy)carbonyl]oxy}ethyl acetate 以 六甲基磷酰三胺 为溶剂， 生成 4-dibenzo[b,f][1,4]thiazepin-11-yl-piperazine-1-carboxylic acid 1-acetoxy-ethyl ester
  参考文献：
  名称：

  WO2008/79839

  摘要：

  公开号：

文献信息

• COMPOUNDS AND USES THEREOF - 150
  申请人：Bernstein Peter

  公开号：US20100016283A1

  公开（公告）日：2010-01-21

  Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.

  以下为公式（I）及其药物可接受的盐或互变异构体，组成物和使用方法。这些新化合物提供了治疗或预防与精神分裂症和其他精神疾患、痴呆症和其他认知障碍、焦虑症、情绪障碍、睡眠障碍、婴幼儿期、童年或青春期通常首次诊断的障碍以及神经退行性疾病相关的至少一种症状或病症的治疗。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS DE CEUX-CI
  申请人：ASTRAZENECA AB

  公开号：WO2008079839A1

  公开（公告）日：2008-07-03

  [EN] This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.
  [FR] L'invention concerne des composés innovants ayant la formule structurale (I) ci-dessus et leur sels ou tautomères pharmaceutiquement acceptables, des compositions et procédés d'utilisation de ceux-ci. Ces composés innovants constituent un traitement ou une prophylaxie d'au moins un symptôme ou une affection associé à la schizophrénie ou à d'autres troubles psychotiques, à une démence et à d'autres troubles cognitifs, à des troubles d'anxiété, à des troubles de l'humeur, à des troubles du sommeil, à des troubles habituellement diagnostiqués pour la première fois au cours de la petite enfance, de l'enfance ou de l'adolescence et de troubles neurodégénératifs.
• [EN] NOVEL DERIVATIVES OF 11-PIPERAZIN-L-YLDIBENZO [B,F] [1,4] THIAZEPINE FOR TREATING AT LEAST ONE SYNDROME OR CONDITION ASSOCIATED WITH SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS<br/>[FR] NOUVEAUX DÉRIVÉS DE 11-PIPÉRAZINE-1-YLDIBENZO [B,F] [1,4] THIAZÉPINE POUR TRAITER AU MOINS UN SYNDROME OU UN ÉTAT ASSOCIÉ À LA SCHIZOPHRÉNIE OU AUTRES TROUBLES PSYCHOTIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2009151392A1

  公开（公告）日：2009-12-17

  This invention relates to novel compounds having the structural Formula I below: (I) and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.